IPSWICH,
Mass. and PARIS,
June 18,
2024 /PRNewswire/ -- New England Biolabs (NEB
®) and Inorevia announce a collaboration to develop
automated workflows to maximize data quality by preparation of
sequence-ready libraries from challenging samples using
NEBNext® library preparation reagents on Inorevia's
Magelia® automation platform.
Preparing high-quality libraries for sequencing analysis from
challenging samples, including those derived from formalin-fixed,
paraffin-embedded (FFPE) tissue, poses several challenges to the
production of high-quality sequencing data. Combining NEB's
innovative NEBNext reagents for next-generation sequencing sample
preparation with Inorevia's unique Magelia® automation
platform results in workflows that improve sequencing performance
by maximizing the number of molecules derived from samples that can
produce accurate sequencing data.
Inorevia, with its headquarters located in the south of
Paris, France, developed and
manufactures its Magelia® automation platform, a unique
liquid handling technology with enhanced kinetics and highly
efficient magnetic bead handling, that unlocks full walk-away
automation of complex workflows. New England Biolabs has been a
leader in the development and manufacture of NGS sample preparation
reagents for over 15 years.
"NEB is a leading company developing and manufacturing not only
extremely efficient enzymes, but a large portfolio of innovative
solutions for scientists around the world. Innovation is at the
core of everything they do, and since our first discussions we felt
our companies were a perfect match in terms of vision. This proved
to be also a great fit in terms of collaboration between our
teams," comments Amel Bendali, Chief Operating Officer and
co-founder at Inorevia.
NEB and Inorevia successfully collaborated on automating whole
genome sequencing (WGS) library prep, including upfront
fragmentation, using the NEBNext®
Ultra™ II FS DNA PCR-free Library Prep Kit for
Illumina® on the Magelia® platform. This
first collaboration demonstrated the Magelia platform's ability to
produce high quality sequencing libraries, demonstrating a
fully-automated workflow from genomic DNA at and even below the
recommended input levels for the kit.
According to Fiona Stewart,
Ph.D., Associate Director, NEBNext Portfolio Management at NEB,
"Inorevia's unique approach provides opportunities to enhance the
performance of enzymatic reactions, driving efficiency on a
molecular level, with reduced sample loss. We're excited about the
potential of combining NEB's unique and highly optimized solutions
for library preparation with the Magelia® platform to
accomplish science that would otherwise be unattainable."
About Inorevia
Co-founded in 2016, Inorevia is a French company exploiting
cutting-edge patented technologies to accelerate Research in Life
Sciences. Inorevia sample prep technology unlocks high resolution
data, even from challenging samples, for a variety of omics
applications. At the core of Inorevia's products lie patented
technologies enabling the preservation of a maximum of molecules of
interest while eliminating background noise from a sample,
ultimately impacting data quality. Inorevia's highly efficient,
intuitive and full walk-away instruments pave the way toward a new
generation of solutions for Life Sciences. Inorevia is a privately
held company headquartered in Bagneux (Paris south), France.
For more information about Inorevia, visit www.inorevia.com
About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. (NEB)
is the industry leader in the discovery and production of enzymes
for molecular biology applications and now offers the largest
selection of recombinant and native enzymes for genomic research.
NEB continues to expand its product offerings into areas related to
PCR, gene expression, sample preparation for next generation
sequencing, synthetic biology, glycobiology, epigenetics and RNA
analysis. Additionally, NEB is focused on strengthening alliances
that enable new technologies to reach key market sectors, including
molecular diagnostics development, as well as nucleic acid
vaccines. New England Biolabs is a privately held company,
headquartered in Ipswich, MA, and
has extensive worldwide distribution through a network of exclusive
distributors, agents and subsidiaries located in Australia, Canada, China, France, Germany, Japan, New
Zealand, Singapore,
South Korea and the UK.
For more information about New England Biolabs visit
www.neb.com.
NEB®, NEW ENGLAND BIOLABS®, and
NEBNext® are registered trademarks of New England
Biolabs, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-england-biolabs-and-inorevia-to-partner-on-novel-solutions-for-the-preparation-of-challenging-samples-for-next-generation-sequencing-302176013.html
SOURCE New England Biolabs, Inc.